Literature DB >> 19451060

Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results.

H R Cárdenes1.   

Abstract

Hepatocellular carcinoma (HCC) is the most frequently occurring primary tumour of the liver in adults and the third most common cause of cancer-related deaths in the world. The incidence of HCC is increasing both in Europe and in the United States due to the increasing prevalence of hepatitis C. Of recognised importance, when making decisions regarding the most appropriate management of a patient with HCC, is the involvement of a multidisciplinary team of hepatologists, hepatobiliary surgeons, a liver transplant team, interventional radiologists, and medical and radiation oncologists. This manuscript reviews the role of stereotactic body radiotherapy in HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19451060     DOI: 10.1007/s12094-009-0355-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  45 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.

Authors:  L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Stereotactic radiotherapy of primary liver cancer and hepatic metastases.

Authors:  Joern Wulf; Matthias Guckenberger; Ulrich Haedinger; Ulrich Oppitz; Gerd Mueller; Kurt Baier; Michael Flentje
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

5.  The use of 3-D dose volume analysis to predict radiation hepatitis.

Authors:  T S Lawrence; R K Ten Haken; M L Kessler; J M Robertson; J T Lyman; M L Lavigne; M B Brown; D J DuRoss; J C Andrews; W D Ensminger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

7.  Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy.

Authors:  J M Robertson; T S Lawrence; L M Dworzanin; J C Andrews; S Walker; M L Kessler; D J DuRoss; W D Ensminger
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

8.  Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.

Authors:  Zhi-Yong Xu; Shi-Xiong Liang; Ji Zhu; Xiao-Dong Zhu; Jian-Dong Zhao; Hai-Jie Lu; Yun-Li Yang; Long Chen; An-Yu Wang; Xiao-Long Fu; Guo-Liang Jiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

View more
  9 in total

1.  CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma.

Authors:  Federico Collettini; Nadja Schreiber; Dirk Schnapauff; Timm Denecke; Peter Wust; Eckart Schott; Bernd Hamm; Bernhard Gebauer
Journal:  Strahlenther Onkol       Date:  2014-11-18       Impact factor: 3.621

2.  Concomitant lung metastasis in patients with advanced hepatocellular carcinoma.

Authors:  Tian Yang; Jun-Hua Lu; Chuan Lin; Song Shi; Ting-Hao Chen; Rong-Hua Zhao; Yi Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

3.  Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy.

Authors:  Sylvain Dewas; Jean-Emmanuel Bibault; Xavier Mirabel; Ingrid Fumagalli; Andrew Kramar; Hajer Jarraya; Thomas Lacornerie; Claire Dewas-Vautravers; Eric Lartigau
Journal:  Radiat Oncol       Date:  2012-10-10       Impact factor: 3.481

4.  A comparison of liver protection among 3-D conformal radiotherapy, intensity-modulated radiotherapy and RapidArc for hepatocellular carcinoma.

Authors:  Dong Chen; Renben Wang; Xiangjiao Meng; Tonghai Liu; Hongjiang Yan; Rui Feng; Shangang Liu; Shumei Jiang; Xiaoqing Xu; Kunli Zhu; Xue Dou
Journal:  Radiat Oncol       Date:  2014-02-06       Impact factor: 3.481

5.  Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.

Authors:  Casey Liveringhouse; Austin Sim; Kosj Yamoah; Michael Poch; Richard B Wilder; Julio Pow-Sang; Peter A S Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

6.  The optimal selection of radiotherapy treatment for hepatocellular carcinoma.

Authors:  Ik Jae Lee; Jinsil Seong
Journal:  Gut Liver       Date:  2012-04-17       Impact factor: 4.519

7.  Prognostic value of serum γ-glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy.

Authors:  Dong Chen; Renben Wang; Xiangjiao Meng; Hongjiang Yan; Shumei Jiang; Rui Feng; Kunli Zhu; Xiaoqing Xu; Xue Dou; Linzhi Jin
Journal:  Oncol Lett       Date:  2014-08-19       Impact factor: 2.967

8.  Identification of Biologically Effective Dose-Volumetric Parameters That Predict Radiation-Induced Hepatic Toxicity in Patients Treated With Helical Tomotherapy for Unresectable Locally Advanced Hepatocellular Carcinoma.

Authors:  Jin Ho Song; Seok Hyun Son; Chul Seung Kay; Hong Seok Jang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

Review 9.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Puja S Venkat; Sarah E Hoffe; Jessica M Frakes
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.